NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status
The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...
J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment
US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...
Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015
Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...
Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...
Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful...
Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province
China-based in vitro fertilization (IVF) specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has announced...
Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital
Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing...
Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH
Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...
Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes
China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...
Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...
China’s CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation
The Center for Drug Evaluation (CDE) in China has announced its 88th batch of reference...
AstraZeneca’s China President Leon Wang Confirmed to Assist in Investigation Amid Fraud Allegations
On October 29, 2024, just hours after celebrating a business school anniversary on social media,...
Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...
Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...
Humanwell Healthcare Receives NMPA Approval for Compound Sodium Lactate Ringer’s Injection
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products...
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...
MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector
US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...
Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...